Best TRT Clinics in 2026: Ranked and Reviewed
For clinically diagnosed hypogonadism, testosterone replacement therapy is legitimate treatment. It is also among the most aggressively marketed categories in all of men's telehealth, and the line between genuine symptom relief and overprescribing blurs easily. Four things decide the ranking below. Diagnostic rigor: symptoms plus two separate morning readings under 300 ng/dL, as the Endocrine Society's 2018 guideline requires, rather than a single test or a questionnaire. Ongoing lab monitoring: PSA and hematocrit drawn at baseline, then again at 3, 6 and 12 months. Formulary breadth: injectable, gel, or fertility-preserving options such as enclomiphene. And pricing you can read. A clinic that prescribes testosterone off a symptom checklist alone is not ranked here at all.
Lowest verified price: $99/mo1 provider compared
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
1 TRT clinics compared · independently scored against our six-factor methodology.
Quick Picks
| # | Provider | Score | |
|---|---|---|---|
| 1 | Brightmeds | Visit |
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
Detailed Reviews
Brightmeds
Best for: flat-priced compounded GLP-1s with TRT and peptides on the same account
Brightmeds sells compounded semaglutide at $129 and tirzepatide at $149 a month, the same at any dose, or $99 and $119 a month on a 3-month pack paid up front. Those prices are for new patients in 38 states and DC and stay locked while the plan runs. It also sells TRT, sermorelin, NAD+ and glutathione, and writes Zepbound vial prescriptions for a $100 consult fee, with LillyDirect billing the drug.
Score Breakdown
Pros
- ✓Semaglutide costs $129 a month, 35% below the $199 median for compounded semaglutide across the sellers we compare
- ✓Tirzepatide costs $149 a month, 45% below the $269 median for compounded tirzepatide across the sellers we compare
- ✓Shows its price before the medical questionnaire, so you can compare it without handing over health information
- ✓The monthly price stays the same as your dose goes up
- ✓The monthly price includes the medication, clinician visits, shipping and lab work
- ✓Serves 47 states
- ✓We found no FDA warning letters issued to Brightmeds
Cons
- ✗Ask which pharmacy fills the prescription before you pay, so you can check its license
- ✗Its compounded semaglutide and tirzepatide are not FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What a TRT clinic has to do before prescribing
Testosterone replacement is real medical therapy, and a diagnostic threshold comes attached to it. That threshold is the dividing line on this page. Some clinics test against it before writing anything and keep testing afterward. Others treat it as paperwork.
What to check
- Two morning draws, not a symptom quiz. Hypogonadism under the Endocrine Society standard needs two separate morning total-testosterone results below 300 ng/dL, together with symptoms that fit. A single draw, an afternoon draw, or a checklist standing in for a lab each puts the prescription outside that guideline.
- Labs after the first prescription. Baseline, three months, six months, then yearly is the cadence for hematocrit and PSA. Above 50% hematocrit, the dose comes down. A clinic drawing blood once at the start has dropped the part of the therapy that prevents harm.
- Formulary, and what it does to fertility. Cypionate by injection is the cheapest and most widely used form. Gel removes the needle and adds a transfer risk to anyone in close contact. Enclomiphene lifts endogenous testosterone and leaves fertility intact. Anyone planning children needs that conversation before a first dose, not after it.
Red flags
- A script written off a questionnaire. Two morning draws below 300 ng/dL, with matching symptoms, are what make a low-testosterone diagnosis defensible. Skipping the confirmatory second test is the pellet-mill pattern. It is not a workup that fell slightly short.
- Hematocrit and PSA checked once, or never. Red blood cell mass rises on testosterone, and an undiagnosed prostate condition can move faster under it. Rechecks at three, six and twelve months are how either gets caught. A clinic running none of them is refilling a prescription, which is a different job from managing a therapy.
- Pellets offered to a first-time patient. Once a pellet is implanted, its dose cannot be lowered. If hematocrit or PSA climbs, the remaining choices are waiting it out or surgery to take it back out. That is a poor position to be in before anyone knows how a patient responds to testosterone.
- Nobody named, no cadence published. Who writes the prescription, and how often the labs repeat, are two facts a clinic can publish. Where a site publishes neither, and the therapy carries genuine cardiovascular and hematologic monitoring requirements, that absence is disqualifying on its own.
Every seller listed above is scored on these criteria under our six-dimension methodology, with prices re-checked against the seller’s own live site.
How we rank, and what counts as “legit”
Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.
Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].
How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].
Frequently Asked Questions
Sources & methodology — as of November 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.